HOUSTON--(BUSINESS WIRE)--Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a research and development biotechnology company, today announced two abstract presentations of the Company’s lead product candidate, TACH101, at the American Society of Clinical Oncology (“ASCO”) Annual Meeting. ASCO is being held virtually from June 4-8, 2021.
“We are excited about the emerging preclinical profile of TACH101, the first inhibitor of KDM4 histone demethylase to be in clinical studies,” stated Frank Perabo, MD, PhD, CEO of Tachyon Therapeutics. “Epigenetic processes play a fundamental role in regulation of cellular biology, but when unregulated, can lead to cancer development and progression. Data presented at ASCO show favorable pharmacologic properties for TACH101, compelling efficacy data in animal models, and broad applicability as a potential anti-cancer agent. We look forward to advancing this molecule into first-in-human trials later this year.”
Highlights from the two ASCO abstracts are summarized below:
- TACH101 demonstrated potent increase in H3 methylation levels (H3K36me3), showing on-target activity.
- TACH101 triggered effective tumor control in xenograft models including colorectal, esophageal, gastric, breast, and lymphoma with tumor growth inhibition of up to 100%.
- Further evaluation using a panel of patient-derived colorectal models and patient-derived organoids showed a strong correlation of TACH101 sensitivity with MSI-H status (IC50 ranges 1-150 nM).
- TACH101 reduced tumorigenic potential by 4.4-fold, suggesting that reduction of cancer stem cells by TACH101 may be effective in therapy-resistant settings.
The poster presentation of Abstract #3105 is available for viewing on the ASCO Annual Meeting website at https://meetinglibrary.asco.org/record/197359/abstract.
- TACH101 showed potent KDM4 inhibition without significant off-target activity in in vitro and in vivo studies.
- Pharmacokinetic studies showed TACH101 exhibited low clearance, moderate volume of distribution, and good oral bioavailability in mouse, rat, and dog.
- TACH101 had little or no inhibitory effects on CYP enzyme activities.
- The exposure from oral administration in rats and dogs was dose proportional and was not affected by food intake in dogs.
Presentation of Abstract #e15067 is available for viewing on the ASCO Annual Meeting website at https://meetinglibrary.asco.org/record/197640/abstract.
About Tachyon Therapeutics Inc.
Tachyon Therapeutics, Inc. is an R&D focused biotechnology company advancing novel, first-in-class therapeutics for the treatment of advanced cancers. Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal – advance our program with speed and innovation, without compromising the quality or integrity of our science. For more information, please visit www.tachyontx.com.
For further information about the Company or Investor information please contact:
Frank Perabo, Chief Executive Officer, 832-952-0829, firstname.lastname@example.org